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In radiotherapy of cancer patients, accurate dose delivery is 
of the utmost importance. Not only to deliver the required 
dose to the tumor, but also to minimize the dose to the 
surrounding healthy tissue. Setup verification is therefore an 
essential part in the radiotherapy chain. Since the late 1950’s 
to present day, setup verification using in-room imaging, has 
evolved dramatically. As a result of this the role and 
responsibilities of the RTT’s in assessing these images and the 
impact on patients’ treatment has changed accordingly. 
Initially, the most commonly used in-room imaging modality 
was megavoltage films. Only the bony structures could be 
visualized on these films. The RTT or the physician checked 
the position of the patient using these films, typically only 
during the first treatment session.  
A big step forward occurred in the 1990’s with the 
introduction of portal imaging as a digital replacement of 
megavoltage films. The images were directly available and 
registration was automated. However, anatomical 
information was still limited and in 2D. The most used 
treatment techniques (AP/PA, 3vs or 4vs) resulted in large 
treatment fields and unnecessary irradiation of healthy 
tissue.  
Not only bony structures, but also soft tissue can be 
visualized more accurately with the introduction of advanced 
in-room imaging techniques in the beginning of this century, 
like CT-on rails and Cone-Beam CT. Also advanced treatment 
techniques like IMRT and VMAT are becoming standard 
clinical practice. Together with improved in-room imaging 
target volumes can be reduced and healthy tissue can be 
spared. An important role for the RTT´s is to verify not only 
setup but also to ascertain if changes in anatomy during the 
RT course could result in under dosage of the tumor or over 
dosage of the organs at risk, resulting in an adaptation of the 
treatment plan. Moreover, the creation of a library of plans 
and daily selection of the optimal plan based on anatomical 
information is currently being evaluated. 
In the last decade, the role of MR in radiotherapy has become 
increasingly important. The excellent soft tissue contrast of 
MR not only allows accurate tumor delineation, but also 
functional information of the tissue becomes available. As 
tumor delineation becomes more accurate, target volumes 
can be more accurately defined. 
The development towards the integration of an MR and a 
treatment machine considerably improves the soft-tissue 
contrast and even functional information is available for 
image guidance. This improved image quality has the 
potential to enable daily re-planning in clinical practice. MR 
guidance entails an important change for the RTT’s, not only 
in image evaluation but also in decision making concerning 
the treatment. Changes in tumor position or tumor behavior 
are available during treatment and personalized 
intervention/adaption of the plan becomes possible. 
Conclusion: In-room image guidance is continuously evolving 
from setup verification on low contrast 2D megavoltage films 
with standardized treatment fields, towards MR guidance and 
adaptation, minimizing target volumes and optimizing 
treatment for the individual patient. 
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Survival rates for lung cancer patients treated with 
radiotherapy (RT) are poor partly due to the high rates of 
local recurrence. It has been shown that the local control 
rate may be improved for non-small cell lung cancer patients 
by increasing the RT dose. However, this requires high 
precision in the daily RT delivery, in order to minimize 
margins and avoid unacceptable normal tissue toxicity. 
Large treatment margins have been used for lung tumours to 
account for respiratory motion and interfractional changes in 
the position of the primary tumour and the lymph nodes.  
The respiratory motion may be taken into account by use of 
time resolved 4D CT scans, whereby the respiratory motion of 
the individual patient is visualized. Implementation of gated 
treatment may lead to a larger margin reduction.  The use of 
FDG-PET for target identification and delineation has 
increased the accuracy due to its high sensitivity and 
specificity. 
The anatomy of the patient may change during the treatment 
course which leads to interfrational shifts in the position of 
the tumour and the lymph nodes. The most commonly used 
setup is based on the bony anatomy of the patient. However, 
a soft tissue match using the tumour reduces the treatment 
margins significantly. Minimal margins require daily online 
tumour match using for instance CBCT scans before each 
treatment fraction. In the majority of the patients, one or 
more of the lymph nodes are found to be malignant which 
complicates the soft tissue match as the nodes and the 
primary tumour may be subject to different interfractional 
shifts and thus, setup on both targets will not be perfect. It 
was found that setup on the primary tumour lead to 
underdosage of the lymph nodes in 10% of the patients[1]. In 
order to account for this, a threshold value for the 
interfractional shift may be used to select patients with 
systematic deviations above the threshold for re-scanning and 
re-planning, i.e. adaptive radiotherapy (ART).  
ART is a radiation treatment process where the treatment 
plan can be modified using systematic feedback of 
measurements [2]. In case of anatomical changes this implies 
re-scanning and re-optimization of the treatment plan.  
Tumour shrinkage and irreproducible fixation may lead to 
systematic interfractional shift of the tumour and the lymph 
nodes. Large anatomical changes are observed in 23 % of the 
patients[3]. These changes include appearance / 
disappearance of an atelectasis, pleural effusion or 
pneumonia/pneumonitis.  These changes may lead to 
geometrical changes of the targets and/or to dosimetrical 
changes due to changes in the density of the tissue (see Fig 
1). In both cases underdosage of the tumour/lymph nodes or 
overdosage of the normal tissue may result.  It has been 
shown that anatomical changes have a larger impact on the 
dose distribution than changes in the respiratory motion or 
interfractional shifts[4]. Therefore, most patients 
experiencing anatomical changes may benefit from 
ART[3,5,6]. 
In addition, tumour shrinkage during the RT course, enables 
dose escalation to the primary tumour with without 
increasing the normal tissue toxicity[7]. 
The implementation of ART requires education of the 
radiation therapists. In our clinic, a programme with e-
learning, hands on training and an individual test was setup 
before clinical start. Furthermore, ART requires a well-
defined workflow for re-scanning and re-planning of quite a 
lot of patients. And finally, daily online soft tissue matching 
followed by evaluation of the tumour and lymph nodes will 
prolong the treatment time compared to a bony anatomy 
match. In our clinic the treatment time was prolonged by 3 
minutes. 
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Toxicity is an inevitable consequence of cancer treatment.   
While patients want curative treatment if possible, quality of 
life issues have been somewhat neglected in the race to 
improve survival.   Patient reported outcome measures 
(PROMS) confirm that most routinely used clinical scoring 
systems fail to identify important toxicities and as a result 
the frequency, severity and impact on patients’ lives of 
chronic GI consequences of cancer therapies has historically 
not been fully recognised by clinicians.   Nor has it received 
the attention that it deserves in terms of research.  Yet the 
iatrogenically driven morbidity of cancer treatments and 
especially radiotherapy is an important human model of GI 
disease and has already yielded new insights which can be 
applied to benign and malignant diseases. 
In the last 20 years, a largely unheralded but spectacular 
revolution in understanding why toxicity develops, how it 
should be identified, measured and managed has gathered 
speed.   Inaccurate terminology describing toxicity in the 
past has significantly hindered progress.  It is now recognised 
that toxicities rarely affect just one organ system and the 
concept that toxicities after radical treatment are a 
progressive disease, Pelvic Radiation Disease, have helped 
formulate more productive treatment approaches and 
understand future priorities.  Clinical studies now show that 
applying this new understanding allows much GI toxicity 
previously widely regarded as incurable to be ameliorated.  
In addition, biomarkers of radiation toxicity – fibrotic markers 
which can be measured in blood are the most promising – 
offer a much more accurate method of detecting toxicity 
than the current approach of defining toxicity by a change in 
symptoms and this is starting to allow new methods of 
preventing toxicity, to be targeted more accurately.   
It is also increasingly understood that the “consequential 
effect” has a critical role in the development of chronic 
toxicity and that it is driven by factors beyond the control of 
the oncologist. One of the most important of these is the 
composition of the gut microbiota; another is the role of the 
immune system.  Introducing techniques already used by 
other disciplines to manipulate these factors will deliver 
future great rewards in terms of reducing chronic toxicity. 
GI toxicity is a major limiting factor to the advance of 
oncological treatments.  Many new solutions have emerged 
but require the harnessing of a multidisciplinary approach in 
a way that oncology has rarely used up to this point.   
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Intestinal radiation injury may severely hamper quality of life 
during and after treatment of abdominal tumors. Even though 
novel technical advances in treatment delivery have enabled 
more selective irradiation of the tumor, normal tissue 
radiation injury remains the most important dose limiting 
factor of radiotherapy. Hence, there is an urgent need for 
agents that can be administered during radiotherapy to 
prevent and/or reduce radiation-induced intestinal injury. 
These agents should of course not hamper the anti-tumor 
effect of radiation and, ideally, even improve radiation-
induced tumor cell kill.  
Pre-clinical studies have shown that the novel Somatostatin 
analogue Pasireotide effectively reduces radiation-induced 
intestinal injury by preventing post-irradiation pancreatic 
enzyme-dependent intestinal auto-digestion. In our 
experiments Pasireotide was shown to preserve the intestinal 
mucosal surface and to prevent intestinal bacterial 
translocation after radiation exposure. Pasireotide did not 
protect the intestinal stem cells and the beneficial effect of 
Pasireotide could be reversed by pancreatic enzyme 
substitution.  Therefore, Pasireotide does not seem to act as 
a cytoprotector, but to mitigate intestinal radiation injury by 
inhibiting pancreatic exocrine secretion.  
Until recent, knowledge on the effects of Pasireotide on the 
radiation-induced tumor response was scarce or non-existing 
at all. Pre-clinical studies have shown that Pasireotide may 
have a direct inhibiting effect on the growth of certain 
tumors such as neuroendocrine cancers. Moreover, it may 
reduce tumor growth by reducing the availability of growth 
factors such as IGF-1 and VEGF. However, no studies have 
been performed to assess the effect of Pasireotide on 
radiation-induced tumor growth delay. As Pasireotide can 
only be considered for clinical use if it does not hamper the 
anti-tumor effect of radiotherapy, we tested the effect of 
Pasireotide on tumor response to radiation in an animal 
model. The results of this recently performed study may 
enable a trial to test the potential beneficial effect on 
intestinal radiation injury in patients.  
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The increasing number of dose escalation and 
hypofractionation prostate cancer trials is providing us 
excellent opportunities to learn more about ano-rectal, 
